Undesired toxic side effects are still amongst the most common reasons for failure of new chemical entities during late stage drug development and can even lead to costly withdrawals of approved drugs from the market. It is therefore necessary to assess compounds in the early phases of the discovery process reliably for potential geno-, hepato-, nephro and cardiotoxic liabilities in order to reduce development costs and increase research efficiency. High content screening is a cost effective tool to run dedicated toxicity tests on relevant model systems.

Such dedicated assays include micronuclei assays to identify genotoxic effects, cell health studies on heptatocytes and kidney cells, advanced assays on 3D InSight™ Liver Microtissues, or using primary human cells, hypertrophy studies on cardiomyocytes.

But even functional drug discovery HCS assays can provide important information on potential unwanted properties of a compound in addition to the primary effect readout.

Publications using PerkinElmer High-Content Screening Products

For Research Use Only. Not for Use in Diagnostic Procedures.